(Q43853440)

English

Efficacy and safety of alogliptin added to metformin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension study

scientific article published on 5 June 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Efficacy and safety of alogliptin added to metformin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension study (English)

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

type 2 diabetes

1 reference

based on heuristic

inferred from title

1 reference

ChEBI release 2020-05-28

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

placebo-controlled trial

1 reference

based on heuristic

inferred from title

author name string

Y Seino

1

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Y Miyata

2

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

S Hiroi

3

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

M Hirayama

4

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

K Kaku

5

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

publication date

5 June 2012

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Diabetes, Obesity and Metabolism

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

14

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

10

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

927-936

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01620.X

21 January 2018

Global Guideline for Type 2 Diabetes: recommendations for standard, comprehensive, and minimal care.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01620.X

21 January 2018

Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01620.X

21 January 2018

Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01620.X

21 January 2018

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01620.X

21 January 2018

Frequency of severe hypoglycemia requiring emergency treatment in type 1 and type 2 diabetes: a population-based study of health service resource use.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01620.X

21 January 2018

UKPDS 26: Sulphonylurea failure in non-insulin-dependent diabetic patients over six years. UK Prospective Diabetes Study (UKPDS) Group.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01620.X

21 January 2018

Metformin, sulfonylureas, or other antidiabetes drugs and the risk of lactic acidosis or hypoglycemia: a nested case-control analysis.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01620.X

21 January 2018

Overview of the gliptin class (dipeptidyl peptidase-4 inhibitors) in clinical practice

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01620.X

21 January 2018

DPP-4 inhibition and islet function

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01620.X

21 January 2018

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01620.X

21 January 2018

Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01620.X

21 January 2018

GIP and GLP-1, the two incretin hormones: Similarities and differences

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01620.X

21 January 2018

Little enhancement of meal-induced glucagon-like peptide 1 secretion in Japanese: Comparison of type 2 diabetes patients and healthy controls

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01620.X

21 January 2018

Comparison of incretin immunoassays with or without plasma extraction: Incretin secretion in Japanese patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01620.X

21 January 2018

Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01620.X

21 January 2018

Secretory units of islets in transplantation index is a useful clinical marker to evaluate the efficacy of sitagliptin in treatment of type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01620.X

21 January 2018

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01620.X

21 January 2018

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01620.X

21 January 2018

Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01620.X

21 January 2018

Dipeptidyl peptidase-4 inhibitors administered in combination with metformin result in an additive increase in the plasma concentration of active GLP-1.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01620.X

21 January 2018

Efficacy and safety of alogliptin in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, dose-ranging comparison with placebo, followed by a long-term extension study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01620.X

21 January 2018

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01620.X

21 January 2018

Initial Combination Therapy With Alogliptin and Pioglitazone in Drug-Naïve Patients With Type 2 Diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01620.X

21 January 2018

Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA(1C) without causing weight gain or increased hypoglycaemia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01620.X

21 January 2018

Hypoglycaemia with oral antidiabetic drugs: results from prescription-event monitoring cohorts of rosiglitazone, pioglitazone, nateglinide and repaglinide.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01620.X

21 January 2018

Efficacy and safety of alogliptin added to pioglitazone in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label long-term extension study.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01620.X

21 January 2018

Sitagliptin added to treatment with ongoing pioglitazone for up to 52 weeks improves glycemic control in Japanese patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01620.X

21 January 2018

Report of the Committee on the classification and diagnostic criteria of diabetes mellitus

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01620.X

21 January 2018

Inhibition of DPP-4 with Vildagliptin Improved Insulin Secretion in Response to Oral as well as “Isoglycemic” Intravenous Glucose without Numerically Changing the Incretin Effect in Patients with Type 2 Diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01620.X

21 January 2018

Identifiers

10.1111/J.1463-1326.2012.01620.X

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43853440&oldid=2103902891"